Zhimeng Biopharma CB03 Received Orphan Drug Designation from the US FDA
20 Oct 2023 //
PR NEWSWIRE
Zhimeng Biopharma will report positive PIb trial results on its ZM-H1505R
14 Jun 2022 //
PRNEWSWIRE
Zhimeng Biopharma Announces Dosing in CB03 in Phase I Clinical Trial
12 May 2022 //
ASIAONE
Zhimeng Biopharma Begins Dosing of CB03 in PI Clinical Trial
11 May 2022 //
PRNEWSWIRE
Zhimeng Biopharma Beginss Dosing in First-in-Human Trial of CB06
31 Mar 2022 //
PRNEWSWIRE